-
Zynerba's Recent Results Revitalize The Bull Case, But Risks Remain
Friday, September 29, 2017 - 4:52pm | 482Read More...The Street reacted to Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)’s positive Fragile X trial results with marked ambivalence. Investors propelled the stock 76 percent higher even as biotech and behavioral experts published critical reviews. Two analysts assigned Hold ratings, but Piper Jaffray...
-
Piper Jaffray Sees Strength In Geron After News Of Drug Development
Monday, December 7, 2015 - 11:29am | 267Read More...Piper Jaffray on Monday issued a company note on Geron Corporation (NASDAQ: GERN) after news of new drug developments at the ASH 2015 conference. Piper Jaffray rates Geron as Overweight and raised the company's price target from $5.00 to $10.00. Analysts Charles Duncan and Sarah Weber wrote...
